Chevy Chase Trust Holdings LLC Sells 9,383 Shares of Amgen Inc. $AMGN

Key Points

• Chevy Chase Trust trimmed its Amgen stake by 3.2% in Q3, selling 9,383 shares and now holding 280,645 shares (about 0.05% of the company) valued at roughly $79.2 million.
• Amgen beat quarterly estimates (EPS $5.29 vs. $4.76; revenue $9.87B vs. $9.46B), issued FY2026 EPS guidance of 21.600–23.000, and declared a $2.52 quarterly dividend ($10.08 annual, 2.8% yield).
• Heavy institutional interest (76.5% ownership) amid large position changes by firms like Laurel Wealth, Norges Bank and Vanguard, while analysts show mixed views with a consensus "Hold" and a $354 target.

Chevy Chase Trust Holdings LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 280,645 shares of the medical research company's stock after selling 9,383 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.05% of Amgen worth $79,198,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Laurel Wealth Advisors LLC raised its holdings in Amgen by 27,765.8% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company's stock worth $1,870,880,000 after purchasing an additional 6,676,575 shares during the last quarter. Norges Bank bought a new stake in shares of Amgen in the 2nd quarter valued at $1,663,726,000. Capital World Investors boosted its stake in shares of Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Amgen by 1.6% during the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company's stock worth $14,996,807,000 after buying an additional 841,117 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Amgen by 5.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company's stock worth $3,600,043,000 after buying an additional 687,735 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AMGN shares. The Goldman Sachs Group boosted their target price on shares of Amgen from $403.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday, February 4th. Wall Street Zen downgraded Amgen from a "buy" rating to a "hold" rating in a report on Saturday, February 21st. Argus lifted their price objective on Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Friday, February 6th. HSBC reissued a "buy" rating and issued a $425.00 price objective on shares of Amgen in a research note on Wednesday, December 10th. Finally, BMO Capital Markets raised their target price on Amgen from $335.00 to $372.00 and gave the stock an "outperform" rating in a research note on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $354.00.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen NASDAQ: AMGN Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis - Amgen, Inc.

Amgen Trading Down 0.4%

NASDAQ:AMGN opened at $366.21 on Friday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a market capitalization of $197.41 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 3.63 and a beta of 0.45. The firm has a fifty day simple moving average of $357.73 and a two-hundred day simple moving average of $325.42.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business's quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.8%. Amgen's dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.